Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apitegromab long-term extension in type 2 and type 3 spinal muscular atrophy
2022-001771-14Phase 3Active
- Sponsor
- Scholar Rock
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apitegromab in spinal muscular atrophy (SMA), sponsored by Scholar Rock. Primary endpoint: Incidence of TEAEs and SAEs by severity. Started Dec 2022; status: active.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2022-001771-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001771-14.